Get the Stockscreener App
98.83
10.71%
9.56
After Hours:
98.83
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $98.83, with a volume of 31.25M.
It is up +10.71% in the last 24 hours and up +9.06% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$89.27
Open:
$95.29
24h Volume:
31.25M
Relative Volume:
2.34
Market Cap:
$172.14B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
27.53
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+4.69%
1M Performance:
+9.06%
6M Performance:
-18.83%
1Y Performance:
-24.98%
1-Day Range:
$94.99
$101.87
1-Week Range:
$87.64
$101.87
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
98.83 | 155.49B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
331.20 | 121.31B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.56 | 103.01B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.62 | 63.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.84 | 50.25B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott (ABT) Receives Outperform Rating Amid Positive Q2 Results - GuruFocus
Abbott Stock Is Leading the S&P 500 After Earnings for Its Best Day in 24 Years - Barron's
Abbott Labs Draws Bullish Targets As Legal Overhang Fades - timothysykes.com
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
Abbott Laboratories (ABT) Shares Surge Over 10% After Strong Q2 Earnings - GuruFocus
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street - MarketBeat
Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise - marketscreener.com
Why Is Abbott Stock Skyrocketing Thursday?Abbott Laboratories (NYSE:ABT) - Benzinga
Dow Jones Hangs On While Memory Chips Take Another Beating - The Motley Fool
Abbott stock powers through 100-DMA, but long-term downtrend still looms - MSN
Abbott (ABT) Shares Rise 10.7% - GuruFocus
Abbott Q2 2026 earnings beat, raises full-year profit guidance - qz.com
Abbott Laboratories shares jump as earnings beat estimates and company raises 2026 outlook - Yahoo Finance
Abbott Labs beats Q2 estimates, raises 2026 out... - Pluang
Stocks making the biggest moves midday: Manpower, Abbott, UnitedHealth, TSMC & more - CNBC
Abbott reports $12.6 billion Q2 2026 sales - grafa.com
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market - Yahoo Finance
Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade) (ABT) - Seeking Alpha
Abbott (ABT) Raises Full-Year EPS Guidance Amid Strong Q2 Revenue Growth - GuruFocus
Abbott surges 12% on raised EPS outlook - Breakingthenews.net
Abbott Laboratories Q2 Earnings Call Highlights - Yahoo Finance
Abbott (ABT) Sees Significant Stock Surge of 12.5% - GuruFocus
Earnings call transcript: Abbott beats Q2 2026 estimates and lifts outlook - Investing.com
Abbott (ABT) Sees Significant Gains in Morning Trading - GuruFocus
Abbott Stock Soars 13% On Earnings Beat, Guidance RaiseAbbott Laboratories (NYSE:ABT) - Benzinga
Abbott Raised Its 2026 Outlook After A Solid Quarter - Finimize
Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Abbott Laboratories (ABT) Surges on Upbeat Q2 Earnings and Revis - GuruFocus
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Benzinga
Abbott shares rise 4% as Q2 earnings beat estimates, driven by strong diagnostics growth. - Pluang
Why Abbott Stock Is Reimagining Its Future - Trefis
Updated Cancer Guidelines Reaffirm Cologuard Tests as Preferred Options - Stock Titan
Abbott Q2 Profit Plunges, Lifts FY26 Adj. EPS View, Backs Sales Forecast; Stock Up 11% - RTTNews
Abbott tops earnings estimates, raises outlook as second-half sales ramps up - TechStock²
Abbott Laboratories reports results for the quarter ended June 30Earnings Summary - TradingView
ABT: Abbott Laboratories Exceeds Revenue and EPS Expectations, R - GuruFocus
Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall? - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Surprises With Q2 CY2026 Sales - StockStory
Abbott rises as guidance hike tops expectations - MSN
Abbott raises 2026 profit forecast on strength in diagnostics, heart devices - Reuters
ABT: Abbott Laboratories Exceeds Expectations and Raises Profit Outlook - GuruFocus
Abbott rises 4% after earnings beat and higher full-year profit guidance - XTB.com
Health Giant Abbott Jumps After Hiking 2026 Profit View - Investor's Business Daily
Abbott raises 2026 earnings outlook after second-quarter results beat expectations (ABT) - Yahoo Finance
Abbott rises as guidance hike tops expectations (ABT:NYSE) - Seeking Alpha
Abbott Laboratories projects Q3 adjusted EPS of $1.38-$1.46 - scanx.trade
Abbott Reports Q2 2026 Results, Raises Full-Year Adjusted EPS Guidance to $5.45–$5.60 - scanx.trade
Abbott (ABT) Reports Strong Q2 Performance with Revenue Growth - GuruFocus
Earnings snapshot: Abbott Laboratories tops Q2 estimates, lifts FY26 adjusted EPS outlook range above consensus - MSN
Why Abbott earnings are sending the stock higher - MSN
Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance - ChartMill
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):